VEGFA and neoplasm: The nanomedicine PCN-Len NPs loaded with lenvatinib target tyrosine kinases in vascular endothelial cells to downregulate the expression of VEGF-A and Ang-2 and reduce micro vessel density, and the p (Man-IMDQ) NRs reduce pro-angiogenic activity through mannose receptor by repolarize pro-angiogenic M2 TAMs to anti-angiogenic M1, further reducing VEGF secretion, impeding the migration and proliferation of vascular endothelial cells, enhancing the anti-tumor angiogenic effect of lenvatinib (Liu X. et al., 2023).